Early Phase Trial Unit

THE TISCH CANCER INSTITUTE

CONNECT WITH US

Key to advancing optimal cancer care is the pursuit of novel therapies—based on scientific investigation—that lead to the best outcomes while minimizing adverse events.

The Early Phase Trial Unit at The Tisch Cancer Institute, under the leadership of Thomas Marron, MD, PhD, facilitates early phase clinical trials that are designed to maximize the development of cutting-edge therapies. With an emphasis on first-in-human and biomarker-focused proof-of-concept studies, the Early Phase Trial Unit promotes the translation of scientific discoveries from the Institute’s laboratories to clinical applications that may favorably impact patient outcomes. New agents may be piloted or used in novel combination with other agents, or they may be administered in ways hypothesized to be more effective, such as injections directly into tumors.

The Early Phase Trial Unit facilitates the Institute's rapid progress in cancer immunotherapy and serves as a hub for precision medicine clinical trials by fostering seamless integration of oncology, genomics, computational biology, pathology, interventional and diagnostic radiology, and medical and surgical specialties.

To submit a referral, please contact us and deliver as much of the following information as possible: contact phone number, patient name, MRN, DX, previous Anti-PD1 (Yes/No), mets accessible for intratumoral injection (yes/no).

Find A Clinical Trial Find Early Phase Clinical Trials Submit a Referral